ApconiX Is Offering an Industrial Immunotoxicology Research/Development Internship
The closing date for this job vacancy has passed. Please visit our Come and Join Us page for current vacancies. If you believe you have the skills and experience and would like to become part of our team please send your speculative CV to careers@apconix.com
ApconiX is a team of non-clinical safety experts formed in 2015 by three scientists with the drive and ambition to create a world-renowned company. Our services include target safety assessments, ion channel screening and project toxicology.
We are a growing company, and this Immunotoxicology Research/Development Internship is a great opportunity to gain key industrial experience and contribute to the advancement of science in pharmaceuticals.
We are based at Alderley Park, the UK’s largest science park in the heart of the beautiful Cheshire countryside, close to Manchester and its International Airport (10 miles) and with direct trains to London every hour from Wilmslow/Macclesfield.
The Challenge:
Immune safety concerns are one of the major causes of drug failure and has been the reason for some of the most notorious drug disasters in history. Therefore, the prediction, mitigation and management of immunotoxicological issues are important challenges in pharmaceutical product development. With better understanding of the potential toxicities of intended and unintended immunological effects of drugs, we can design optimised preclinical programmes, make more informed decisions in drug development which will ultimately lead to better outcomes for patients.
The Team:
At ApconiX our target safety group deliver high quality assessments of the on-target liabilities of target modulation to a global pharmaceutical industry client base. These assessments are built on the compilation and the review/interpretation of scientific literature for a given therapeutic approach. Our team consists of multidisciplinary members who work collaboratively to find, interpret and advise clients on how to mitigate potential risks associated with their novel drugs.
The Role:
This exciting role is a hybrid of research/development in our immunotoxicology capability and an opportunity to contribute to the delivery of our state of the art target safety assessment service in two areas:
- The construction of resources and tools used to assess the key mechanisms of immunotoxicity. This will be supported by our immunotoxicology expert.
- Developing personal skills in the assessment of target safety. The necessary training and support will enable you to translate in vivo, in vitro and in silico datasets into meaningful toxicological information and guidance on novel drug targets. This element will be supported by our target safety and modality team.
This salaried internship is ideal for a candidate with a pharmacology/toxicology (BSc, MSc) background and an interest in immunotoxicology who may be considering post-graduate studies or who would like to gain critical industrial experience. ApconiX is a supportive environment within which you can develop your career in drug discovery.
Candidate Requirements:
Qualified to BSc, MSc or PhD level in life sciences e.g. pharmacology/toxicology or similar
- An enthusiasm for immunotoxicology and mechanistic toxicology challenges
- High-quality scientific writing
- Effective communication and collaboration skills
- Ability to curate and interrogate complex datasets
- Research integrity
- Working knowledge of drug discovery process
- The ability to manage complex and conflicting deadlines
- UK right of abode
ApconiX is flexible in terms of internship length of between 6 and 12 months.
Download the Immunotoxicology Research/Development Internship job description.
How to Apply:
Please submit a CV with covering letter to careers@apconix.com by 20th September 2023. ApconiX reserves the right to close the post when the suitable candidate comes forward. For more information, contact sean.hammond@apconix.com, ruth.roberts@apconix.com or james.sidaway@apconix.com. Interviews will take place in October 2023 at the latest.